(VIANEWS) – The NASDAQ opens in less than one hour and Xenetic Biosciences‘s pre-market value is already 10.94% up.
The last session, NASDAQ finished with Xenetic Biosciences (XBIO) dropping 9.82% to $0.59. NASDAQ slid 1.8% to $10,867.93, after four successive sessions in a row of losses, on what was an all-around bearish trend exchanging session.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical firm that focuses on advancing XCART, a customized chimeric receptor T cell (CART) platform technology designed to target specific patient-specific tumour neoantigens. It is involved in research and development of oncology therapies and biologic drugs. Cell-based therapies that target the B-cell receptor are developed to treat B-cell lymphomas. By partnering with pharmaceutical and biotechnology companies, it is also using PolyXen, their proprietary drug delivery platform. Takeda Pharmaceutical Co. Ltd. and Serum Institute of India Limited have signed collaboration agreements. Xenetic Biosciences, Inc. has its headquarters in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of -1.704.
Return on Equity (TTM)
Xenetic Biosciences’s ROE is -42.29.
Today’s last reported volume for Xenetic Biosciences is 48404, 0.94% below its average volume of 48868.
Xenetic Biosciences’s last close was $0.59, 75.78% below its 52-week high of $2.42.
The company’s growth estimates for the ongoing quarter and the next is 20% and 15.4%, respectively.
Xenetic Biosciences’s last day, last week, and last month’s current intraday variation average was 10.88%, 8.66%, and 5.39%, respectively.
Xenetic Biosciences’s highest amplitude of average volatility was 11.76% (day), 11.25% (last week), and 10.32% (last month), respectively.
More news about Xenetic Biosciences (XBIO).